Market Highlights
Global Crohn’s Disease Market has been evaluated as growing market and expected that the market will reach high growth figures in the coming future. Crohn's disease is a type of inflammatory bowel disease (IBD), caused by a combination of environmental, immune and bacterial factors in genetically prone individuals.
The Crohn’s & Colitis Foundation of America (CCFA) stated, that over 1 Million Americans were diagnosed with Crohn's & ulcerative colitis disorders and diseases, with maximum of them aged above 30. Increasing occurrence of Crohn's disease has triggered a vigorous demand for its therapeutics.
The global Crohn’s disease market size is expected to register ~3.3% CAGR during the forecast period, 2019 to 2025.
A survey conducted by the US Center for Disease Control (CDC) has discovered that the incidence rate of Crohn's disease in the country is 3.1 to 14.6 new cases per 100,000 population annually. The disease is highly predominant in developed countries, especially in individuals who smoke and consume alcohol.
Major factors leading to the growth of the market includes higher preference for symptomatic therapeutic, better treatment of inflammatory bowel diseases, arrival of enhanced drugs and healthier investments in R&D programs. High cost of treatment and lack of early diagnosis techniques are the major factor restricting the market growth.
North America is expected to account for the largest share of the global Crohn’s disease Market in 2016, followed by Europe, the region will continue to lead the pack during the forecast period. The emerging markets of China and India will also play a key role in driving growth in the long term, primarily due to the anticipated strong uptake of Remicade over the forecast period.
Global Crohn’s Disease Market Players:
Key players profiled in the report are Allergan, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, and Bayer AG, UCB S.A., Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc., Ferring B.V.
https://www.marketresearchfuture.com/reports/crohns-disease-market-2344